Market Place
Sourcing Support
All News #Library
Biotech
Biohaven Completes Phase 2 Taldefgrobep Alfa Obesity Trial
19 Mar 2026 //
PR NEWSWIRE
Biohaven Reduces Scope Of R&D Cuts As Pipeline Progresses
03 Mar 2026 //
FIERCE BIOTECH
Biohaven Showcases Advances In Degrader Programs At J.P. Morgan
12 Jan 2026 //
PR NEWSWIRE
Biohaven Updates Phase 2 BHV-7000 Trial in Major Depression
24 Dec 2025 //
PR NEWSWIRE
Biohaven Shares BHV-1510 Safety Data with Cemiplimab at ESMO 2025
11 Dec 2025 //
PR NEWSWIRE
Biohaven Completes Upsized Public Offering, Raises $200M
13 Nov 2025 //
PR NEWSWIRE
Biohaven Prices $175M Public Offering Of Common Shares
12 Nov 2025 //
PR NEWSWIRE
Biohaven Announces Proposed Public Offering Of Common Shares
11 Nov 2025 //
PR NEWSWIRE
Bexorg Collaborates with Biohaven to Enhance CNS Drug Development
10 Jun 2025 //
GLOBENEWSWIRE
Biohaven Shows Early Data On Trop2, FGFR3 ADCs With TopoIx
28 May 2025 //
PR NEWSWIRE
Biohaven lands funding Oberland funding deal worth up to $600M
29 Apr 2025 //
FIERCE BIOTECH
Biohaven Showcases Neuroscience Portfolio at 2025 AAN Meeting
05 Apr 2025 //
PR NEWSWIRE
Biohaven Reports Q4, Full-Year 2024 Financials, Business Updates
03 Mar 2025 //
PR NEWSWIRE
Biohaven`s BHV-1300 Shows >80% IgG Reduction In Degrader Data
03 Mar 2025 //
PR NEWSWIRE
Merus & Biohaven To Co-Develop 3 Novel Bispecific ADC Programs
12 Jan 2025 //
GLOBENEWSWIRE
Biohaven Doses First Patient With Novel Trop-2 ADC BHV-1510
30 May 2024 //
PR NEWSWIRE
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat
16 Oct 2023 //
PR NEWSWIRE
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa
14 Sep 2023 //
PR NEWSWIRE
Biohaven`s Taldefgrobep Alfa receives FDA Fast Track Designation
21 Feb 2023 //
CONTRACT PHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.